Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 2 Nemolizumab Trial Opens for CPUO
2
Addressing Delays in Prior Authorization Processes That Negatively Impact Patients
3
JAK Inhibitors Show Comparable Safety to TNF Antagonists
4
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
5
